Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β-Lactamase-Producing Enterobacteriaceae in the Neutropenic Murine Lung Infection Model.
Asempa TE, Motos A, Abdelraouf K, Bissantz C, Zampaloni C, Nicolau DP. Asempa TE, et al. Among authors: bissantz c. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02382-18. doi: 10.1128/AAC.02382-18. Print 2019 Apr. Antimicrob Agents Chemother. 2019. PMID: 30670411 Free PMC article.
Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA).
Malherbe P, Roche O, Marcuz A, Kratzeisen C, Wettstein JG, Bissantz C. Malherbe P, et al. Among authors: bissantz c. Mol Pharmacol. 2010 Jul;78(1):81-93. doi: 10.1124/mol.110.064584. Epub 2010 Apr 19. Mol Pharmacol. 2010. PMID: 20404073
Translating pharmacology models effectively to predict therapeutic benefit.
Dudal S, Bissantz C, Caruso A, David-Pierson P, Driessen W, Koller E, Krippendorff BF, Lechmann M, Olivares-Morales A, Paehler A, Rynn C, Türck D, Van De Vyver A, Wang K, Winther L. Dudal S, et al. Among authors: bissantz c. Drug Discov Today. 2022 Jun;27(6):1604-1621. doi: 10.1016/j.drudis.2022.03.009. Epub 2022 Mar 15. Drug Discov Today. 2022. PMID: 35304340 Free article. Review.
Discovery of RO7185876, a Highly Potent γ-Secretase Modulator (GSM) as a Potential Treatment for Alzheimer's Disease.
Ratni H, Alker A, Bartels B, Bissantz C, Chen W, Gerlach I, Limberg A, Lu M, Neidhart W, Pichereau S, Reutlinger M, Rodriguez-Sarmiento RM, Jakob-Roetne R, Schmitt G, Zhang E, Baumann K. Ratni H, et al. Among authors: bissantz c. ACS Med Chem Lett. 2020 Apr 27;11(6):1257-1268. doi: 10.1021/acsmedchemlett.0c00109. eCollection 2020 Jun 11. ACS Med Chem Lett. 2020. PMID: 32551009 Free PMC article.
In Vivo Efficacy of Meropenem with a Novel Non-β-Lactam-β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model.
Monogue ML, Giovagnoli S, Bissantz C, Zampaloni C, Nicolau DP. Monogue ML, et al. Among authors: bissantz c. Antimicrob Agents Chemother. 2018 Aug 27;62(9):e02596-17. doi: 10.1128/AAC.02596-17. Print 2018 Sep. Antimicrob Agents Chemother. 2018. PMID: 30012751 Free PMC article.
Can we discover pharmacological promiscuity early in the drug discovery process?
Peters JU, Hert J, Bissantz C, Hillebrecht A, Gerebtzoff G, Bendels S, Tillier F, Migeon J, Fischer H, Guba W, Kansy M. Peters JU, et al. Among authors: bissantz c. Drug Discov Today. 2012 Apr;17(7-8):325-35. doi: 10.1016/j.drudis.2012.01.001. Epub 2012 Jan 16. Drug Discov Today. 2012. PMID: 22269136 Review.
41 results